Table of Contents Author Guidelines Submit a Manuscript
International Journal of Breast Cancer
Volume 2017, Article ID 4537532, 6 pages
https://doi.org/10.1155/2017/4537532
Research Article

P-Rex1 Expression in Invasive Breast Cancer in relation to Receptor Status and Distant Metastatic Site

1Department of Pathology & Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
2Comprehensive Breast Program, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
3Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hanover, NH, USA
4Department of Molecular & Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA

Correspondence should be addressed to Todd W. Miller; ude.htuomtrad@rellim.w.ddot

Received 17 February 2017; Accepted 7 May 2017; Published 15 June 2017

Academic Editor: Debra A. Tonetti

Copyright © 2017 Jonathan D. Marotti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

Figure S1: P-REX1 immunohistochemical controls. A) Positive control; MCF-7 breast cancer xenograft that expresses P-Rex1 (x155). B) Positive control; ZR75-1 breast cancer cells transfected with non-silencing control siRNA (x145). C) Negative control; ZR75-1 breast cancer cells transfected with siRNA targeting P-Rex1 (x145). Figure S2: Univariate and multivariate analyses of associations between clinical and pathologic features and P-Rex1 histoscore. Based on univariate analyses (shown below), we found that primary tumor subtype and grade were significantly associated with P-Rex1 histoscore; these covariates were included in a multivariate linear model as follows: Subtype: TN vs. other, Grade: Intermediate vs. other. Primary tumor subtype (p = 0.04) and grade (p = 0.006) remained significantly associated with P-Rex1 histoscore in the multivariate analysis (multiple R2 = 0.16, p = 0.001).

  1. Supplementary Material